Advertisement

Gastro-News

, Volume 6, Issue 6, pp 48–50 | Cite as

Probiotika

Mikrobiommodulation

  • Joachim LabenzEmail author
fortbildung
  • 3 Downloads

Es gibt heute zahlreiche wissenschaftliche Untersuchungen zu oralen Probiotika bei unterschiedlichen Erkrankungen sowie zu deren Wirkmechanismen. Inzwischen ist bekannt, dass die Wirksamkeit von probiotischen Bakterien sowohl stamm- als auch krankheitsspezifisch ist.

Literatur

  1. 1.
    McFarland LV et al. Strain-Specificity and Disease-Specificity of Probiotic Efficacy: A Systematic Review and Meta-Analysis. Front Med (Lausanne). 2018;5:124CrossRefGoogle Scholar
  2. 2.
    Sniffen JC et al. Choosing an appropriate probiotic product for your patient: An evidence-based practical guide. PLoS One. 2018; 13(12): e0209205CrossRefGoogle Scholar
  3. 3.
    Piche T. Tight junctions and IBS—the link between epithelial permeability, low-grade inflammation, and symptom generation? Neurogastroenterol Motil. 2014;26(3):296–302.CrossRefGoogle Scholar
  4. 4.
    Lacy BE et al. Rome Criteria and a Diagnostic Approach to Irritable Bowel Syndrome. J Clin Med. 2017;6(11):99.CrossRefGoogle Scholar
  5. 5.
    Holtmann GJ, Ford AC, Talley NJ. Pathophysiology of irritable bowel syndrome. Lancet Gastroenterol Hepatol. 2016;1(2):133–146CrossRefGoogle Scholar
  6. 6.
    Stern EK & Brenner DM. Gut Microbiota-Based Therapies for Irritable Bowel Syndrome. Clin Transl Gastroenterol. 2018;9(2):e134.CrossRefGoogle Scholar
  7. 7.
    Lazaridis N, Germanidis G. Current insights into the innate immune system dysfunction in irritable bowel syndrome. Ann Gastroenterol. 2018;31(2):171–187.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Layer P et al. S3-Leitlinie Reizdarmsyndrom: Definition, Pathophysiologie, Diagnostik und Therapie. Z Gastroenterol 2011;49:237–293.CrossRefGoogle Scholar
  9. 9.
    Ducrotte P et al. Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome. World J Gastroenterol. 2012; 18(30) 4012–4018.CrossRefGoogle Scholar
  10. 10.
    Ambrosetti P, Chautems R, Soravia C, et al.: Long-term outcome of mesocolic and pelvic diverticular abscesses of the left colon: a prospective study of 73 cases. Dis Colon Rectum 2005;48:787–791.CrossRefGoogle Scholar
  11. 11.
    Leifeld L et al. 1S2k Leitlinie Divertikelkrankheit / Divertikulitis. AWMF-Registernummer 021/20.Google Scholar
  12. 12.
    Tursi A et al. Moderate to severe and prolonged left lower-abdominal pain is the best symptom characterizing symptomatic uncomplicated diverticular disease of the colon: a comparison with fecal calprotectin in clinical setting. J Clin Gastroenterol. 2015;49(3):218–21.CrossRefGoogle Scholar
  13. 13.
    Scarpignato et al. Management of colonic diverticular disease in the third millennium: Highlights from a symposium held during the United European Gastroenterology Week 2017. Therap Adv Gastroenterol. 2018;11:1756284818771305.CrossRefGoogle Scholar
  14. 14.
    Maconi. Diagnosis of symptomatic uncomplicated diverticular disease and the role of Rifaximin in management. Acta Biomed. 2017; 88(1): 25–32PubMedPubMedCentralGoogle Scholar
  15. 15.
    Barbara G et al. Gut microbiota, metabolome and immune signatures in patients with uncomplicated diverticular disease. Gut. 2017;66(7):1252–1261.CrossRefGoogle Scholar
  16. 16.
    Tursi A et al. Randomised clinical trial: mesalazine and/or probiotics in maintaining remission of symptomatic uncomplicated diverticular disease—a double-blind, randomised, placebo-controlled study. Aliment Pharmacol Ther. 2013;38(7):741–51.CrossRefGoogle Scholar
  17. 17.
    Lübbert et al., Dtsch Med Wochenschr 2018Google Scholar
  18. 18.
    Lübbert C et al. Clostridium-difficile-Infektion. Leitliniengerechte Diagnostik- und Behandlungsoptionen. Dtsch Arztebl Int 2014; 111(43): 723–31.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Grube RF et al. Ökonomische Auswirkungen einer Clostridium-difficile-Enterokolitis in deutschen Krankenhäusern auf der Basis von DRG-Kostendaten. Z Gastroenterol 2015; 53: 391–39.CrossRefGoogle Scholar
  20. 20.
    Goldenberg JZ et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev. 2017 Dec 19;12.Google Scholar
  21. 21.
    Shen NT et al. Timely Use of Probiotics in Hospitalized Adults Prevents Clostridium difficile Infection: A Systematic Review With Meta-Regression Analysis. Gastroenterology. 2017 Jun;152(8):1889–1900.e9.CrossRefGoogle Scholar
  22. 22.
    Gao XW et al. Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients. Am J Gastroenterol. 2010 Jul;105(7):1636–41.CrossRefGoogle Scholar
  23. 23.
    Maziade PJ et al. A Decade of Experience in Primary Prevention of Clostridium difficile Infection at a Community Hospital Using the Probiotic Combination Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2 (Bio-K+). Clin Infect Dis. 2015 May 15;60 Suppl 2:S144–7.CrossRefGoogle Scholar
  24. 24.
    Kamdeu Fansi AA et al. Savings from the use of a probiotic formula in the prophylaxis of antibiotic-associated diarrhea. J Med Econ. 2012;15(1):53–60.CrossRefGoogle Scholar
  25. 25.
    Meyer EA et al. Gut Microbes and the Brain: Paradigm Shift in Neuroscience. J Neurosci. 2014 Nov 12;34(46):15490–15496.CrossRefGoogle Scholar
  26. 26.
    Klimovich AV et al. Rethinking the Role of the Nervous System: Lessons From the Hydra Holobiont. Bioessays. 2018 Sep;40(9):e1800060.CrossRefGoogle Scholar
  27. 27.
    Yano JM et al. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell. 2015 Apr 9;161(2):264–76.CrossRefGoogle Scholar
  28. 28.
    Emeran Mayer, Das zweite Gehirn, riva Verlag, 2. Auflage 2017Google Scholar
  29. 29.
    How microbes could cure disease: Rob Knight at TED2014. TED Blog 2014 Mar 19.Google Scholar
  30. 30.
    Tillisch K et al. Consumption of fermented milk product with probiotic modulates brain activity. Gastroenterology. 2013 Jun;144(7):1394–401, 1401.e1-4.CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Diakonie Klinikum, Jung-Stilling-Krankenhaus Akademisches Lehrkrankenhaus der Universität MarburgSiegenDeutschland

Personalised recommendations